Advertisement

Topics

Axxima Pharmaceuticals AG Company Profile

14:37 EST 17th November 2017 | BioPortfolio

Axximaâ„¢ Pharmaceuticals AG (formerly VirGene) is the leader in the application of pathogen-host signal transduction intervention. The company develops proprietary drugs that are based on Axxima's revolutionary approach to generate a Signal Transduction Firewallâ„¢ (STFâ„¢) against pathogens. Axxima's business strategy is to pursue the highly desirable area of anti-infective drug discovery from beginning to end, from target identification to drug development, making it a small pharmaceutical company rather than a traditional platform-based biotechnology startup. Axxima has developed a technology platform directed towards the identification of "critical" interaction points between a pathogen and target cells in the host. Axxima is developing small molecule drugs to interfere at these critical interaction points, thus blocking the pathogen's manipulation of the host cell and leaving the pathogen without the tools with which to establish itself in the host.

Location

Am Klopferspitz 19
Martinsried
Bavaria
D-82152
Germany

Contact

Phone: +49 (0) 89 - 740 165 - 0
Fax: +49 (0) 89 - 740 165 - 20


News Articles [447 Associated News Articles listed on BioPortfolio]

Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals

Pivot Pharmaceuticals plans to acquire the worldwide rights to Altum Pharmaceuticals’ BiPhasix Transdermal drug delivery technology.

Inotek Pharmaceuticals announces merger deal with Rocket Pharmaceuticals

Inotek Pharmaceuticals announced that it has entered into a definitive merger agreement with US-based gene therapy company Rocket Pharmaceuticals.

Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean

TORONTO, ON -- (Marketwired) -- 09/12/17 -- Easton Pharmaceuticals Inc. (OTC PINK: EAPH) and its JV partner BMV Medica SA de CV announces that its distributor Windsor Pharmaceuticals SA has receiv...

Imprimis launches Surface Pharmaceuticals subsidiary

Imprimis Pharmaceuticals, an ophthalmology-focused pharmaceutical company, has filed a Form 8-K with the SEC which contains a corporate presentation for its subsidiary, Surface Pharmaceuticals. Surf...

Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES, CA -- (Marketwired) -- 08/07/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modu...

FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX) for Travelers' Diarrhea

Upon FDA Approval, Aries Pharmaceuticals, Inc. to Lead U.S. Commercial Efforts Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that the U.S. Food and Drug Administration (FDA) has granted b...

Deals this week: Valeant Pharmaceuticals International, Novan, Recursion Pharmaceuticals

Valeant Pharmaceuticals International plans to raise C$1bn ($801.37m) through the private placement of senior secured notes.

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Valeant Pharmaceuticals International has announced the sale of its subsidiary Dendreon Pharmaceuticals for $819.9m to Sanpower Group.

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [119 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Effects of exposure to pharmaceuticals (diclofenac and carbamazepine) spiked sediments in the midge, Chironomus riparius (Diptera, Chironomidae).

Human and veterinary pharmaceuticals and degradation products are continuously introduced into the environment. To date, there is a lack of information about the effects of pharmaceuticals in spiked t...

Clinical Trials [205 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet ...

Companies [1286 Associated Companies listed on BioPortfolio]

Axxima Pharmaceuticals AG

Axximaâ„¢ Pharmaceuticals AG (formerly VirGene) is the leader in the application of pathogen-host signal transduction intervention. The company develops proprietary drugs that are based on Axxima'...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

Avanir Pharmaceuticals

AVANIR Pharmaceuticals, formerly LIDAK Pharmaceuticals, is a development stage company organized to discover, develop, and market novel therapeutic products to treat human diseases.

More Information about "Axxima Pharmaceuticals AG" on BioPortfolio

We have published hundreds of Axxima Pharmaceuticals AG news stories on BioPortfolio along with dozens of Axxima Pharmaceuticals AG Clinical Trials and PubMed Articles about Axxima Pharmaceuticals AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Axxima Pharmaceuticals AG Companies in our database. You can also find out about relevant Axxima Pharmaceuticals AG Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record